Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q2 2025

Holdings as of Jun 30, 2025, filed Aug 13, 2025. Long positions only; changes compare share counts with Q1 2025.

Institution overview
Positions
77
−4 vs. Q1 2025
Portfolio value
$676.3M
+$37.5M (+5.9%) vs. Q1 2025
Filed
Aug 13, 2025
SEC
Holdings of Affinity Asset Advisors, LLC in Q2 2025
SecurityClassSharesValue% of portfolioShare changeActionHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$112<0.1%00.0%Unchanged–
Rocket Pharmaceuticals, Inc.77313F114*W EXP 09/02/20275,000$2.16K<0.1%00.0%Unchanged–
QTTBQ32 Bio Inc.COM27,777$41.4K<0.1%00.0%UnchangedHistory
ADGMAdagio Medical Holdings, Inc.COM80,000$108.0K<0.1%−133,235−62.5%ReducedHistory
RADXRadiopharm Theranostics LtdSPONSORED ADS35,635$166.1K<0.1%−28,965−44.8%ReducedHistory
OVIDOvid Therapeutics Inc.COM667,516$220.2K<0.1%00.0%UnchangedHistory
ZURAZura Bio LtdCLASS A ORD SHS223,335$234.5K<0.1%00.0%UnchangedHistory
RPTXRepare Therapeutics Inc.COM200,000$278.0K<0.1%00.0%UnchangedHistory
ENGNenGene Therapeutics Inc.COM77,000$280.3K<0.1%+77,000NewHistory
CNTXContext Therapeutics Inc.COM518,025$339.4K0.1%−142,564−21.6%ReducedHistory
TSHATaysha Gene Therapies, Inc.COM SHS200,000$462.0K0.1%+200,000NewHistory
STROSutro Biopharma, Inc.COM752,722$537.4K0.1%00.0%UnchangedHistory
JBIOJade Biosciences, Inc.COM NEW65,317$652.5K0.1%+65,317NewHistory
ABVXAbivax S.A.SPONSORED ADS100,000$765.0K0.1%−100,000−50.0%ReducedHistory
OKUROnKure Therapeutics, Inc.COM CL A347,990$831.7K0.1%−46,169−11.7%ReducedHistory
NXTCNextCure, Inc.COM2,302,598$1.06M0.2%00.0%UnchangedHistory
OLMAOlema Pharmaceuticals, Inc.COM250,000$1.06M0.2%−75,000−23.1%ReducedHistory
SVRASavara IncCOM500,000$1.14M0.2%+500,000NewHistory
MIRMMirum Pharmaceuticals, Inc.COM24,692$1.26M0.2%−25,000−50.3%ReducedHistory
NKTXNkarta, Inc.COM800,000$1.33M0.2%00.0%UnchangedHistory
ATXSAstria Therapeutics, Inc.COM300,000$1.61M0.2%+300,000NewHistory
AVRAnteris Technologies Global Corp.COM425,000$1.61M0.2%+35,000+9.0%AddedHistory
CLYMClimb Bio, Inc.COM1,500,000$1.86M0.3%00.0%UnchangedHistory
QUREuniQure N.V.SHS135,000$1.88M0.3%−265,000−66.3%ReducedHistory
NAMSWNewAmsterdam Pharma Co N.V.*W EXP 11/22/202245,000$1.96M0.3%+3,043+1.3%AddedHistory
CGEMCullinan Therapeutics, Inc.COM263,817$1.99M0.3%00.0%UnchangedHistory
THRDThird Harmonic Bio, Inc.COM370,000$2.01M0.3%00.0%UnchangedHistory
GERNGeron CorpCOM1,500,000$2.12M0.3%00.0%UnchangedHistory
RAPPRapport Therapeutics, Inc.COM199,643$2.27M0.3%+199,643NewHistory
MNPRMonopar TherapeuticsCOM NEW67,500$2.42M0.4%+5,500+8.9%AddedHistory
JAZZJazz Pharmaceuticals plcSHS USD25,000$2.65M0.4%+25,000NewHistory
OACCUOaktree Acquisition Corp. III Life SciencesUNIT 10/04/2029250,000$2.65M0.4%00.0%UnchangedHistory
AVTXAvalo Therapeutics, Inc.COM NEW607,872$3.03M0.4%−49,282−7.5%ReducedHistory
CATXPerspective Therapeutics, Inc.COM NEW1,050,000$3.61M0.5%−1,174,196−52.8%ReducedHistory
MRUSMerus N.V.COM70,000$3.68M0.5%−251,962−78.3%ReducedHistory
FRNMFreenome, Inc.CL A ORD SHS350,000$3.71M0.5%00.0%UnchangedHistory
PCVXVaxcyte, Inc.COM125,000$4.06M0.6%+100,000+400.0%AddedHistory
CRNXCrinetics Pharmaceuticals, Inc.COM152,252$4.38M0.6%00.0%UnchangedHistory
ROIVRoivant Sciences Ltd.SHS400,000$4.51M0.7%+250,000+166.7%AddedHistory
CBIOCrescent Biopharma, Inc.COM280,031$4.52M0.7%+280,031NewHistory
NAMSNewAmsterdam Pharma Co N.V.ORDINARY SHARES275,000$4.98M0.7%−50,000−15.4%ReducedHistory
ERASErasca, Inc.COM4,085,787$5.19M0.8%+744,268+22.3%AddedHistory
AXSMAxsome Therapeutics, Inc.COM50,000$5.22M0.8%−50,000−50.0%ReducedHistory
VRDNViridian Therapeutics, Inc.COM390,000$5.45M0.8%00.0%UnchangedHistory
BBIOBridgeBio Pharma, Inc.COM150,000$6.48M1.0%−150,000−50.0%ReducedHistory
Travere Therapeutics, Inc.89422GAA5NOTE 2.250% 3/0–$6.69M1.0%–––
ORKAOruka Therapeutics, Inc.COM603,479$6.76M1.0%+58,117+10.7%AddedHistory
AUTLAutolus Therapeutics plcSPON ADS3,045,000$6.94M1.0%00.0%UnchangedHistory
INZYInozyme Pharma, Inc.COM1,749,359$7.00M1.0%−2,118,351−54.8%ReducedHistory
Omeros Corp682143AK8NOTE 9.500% 6/1–$7.07M1.0%–New–
AKBAAkebia Therapeutics, Inc.COM1,950,000$7.10M1.0%+450,000+30.0%AddedHistory
PRQRProQR Therapeutics N.V.SHS EURO3,499,512$7.14M1.1%+215,000+6.5%AddedHistory
ELVNEnliven Therapeutics, Inc.COM400,000$8.02M1.2%+400,000NewHistory
SYRESpyre Therapeutics, Inc.COM NEW606,678$9.08M1.3%+125,000+26.0%AddedHistory
VTYXVentyx Biosciences, Inc.COM4,536,182$9.71M1.4%+4,536,182NewHistory
RZLTRezolute, Inc.COM NEW2,200,000$9.81M1.5%+500,000+29.4%AddedHistory
NRIXNurix Therapeutics, Inc.COM967,620$11.0M1.6%+156,951+19.4%AddedHistory
Karyopharm Therapeutics Inc.48576UAA4NOTE 3.000%10/1–$11.6M1.7%–––
CNTACentessa Pharmaceuticals plcSPONSORED ADS900,162$11.8M1.7%−646,500−41.8%ReducedHistory
MLYSMineralys Therapeutics, Inc.COM900,000$12.2M1.8%−200,000−18.2%ReducedHistory
VERAVera Therapeutics, Inc.CL A545,000$12.8M1.9%+189,857+53.5%AddedHistory
WVEWave Life Sciences, Inc.SHS2,000,308$13.0M1.9%+175,308+9.6%AddedHistory
TRVITrevi Therapeutics, Inc.COM2,534,058$13.9M2.0%+1,284,058+102.7%AddedHistory
ESTAEstablishment Labs Holdings Inc.COM334,863$14.3M2.1%+54,863+19.6%AddedHistory
TVTXTravere Therapeutics, Inc.COM970,000$14.4M2.1%−100,000−9.3%ReducedHistory
LXEOLexeo Therapeutics, Inc.COM3,589,355$14.4M2.1%+2,108,474+142.4%AddedHistory
TEVATeva Pharmaceutical Industries LtdSPONSORED ADS1,400,000$23.5M3.5%00.0%UnchangedHistory
MDGLMadrigal Pharmaceuticals, Inc.COM80,000$24.2M3.6%00.0%UnchangedHistory
PTGXProtagonist Therapeutics, IncCOM440,000$24.3M3.6%+40,000+10.0%AddedHistory
ALKSAlkermes plc.SHS1,000,000$28.6M4.2%00.0%UnchangedHistory
APGEApogee Therapeutics, Inc.COM691,899$30.0M4.4%−459,300−39.9%ReducedHistory
NUVLNuvalent, Inc.COM415,000$31.7M4.7%−45,000−9.8%ReducedHistory
BPMCBlueprint Medicines CorpCOM250,000$32.0M4.7%+250,000NewHistory
ACLXArcellx, Inc.COMMON STOCK495,000$32.6M4.8%−35,000−6.6%ReducedHistory
XENEXenon Pharmaceuticals Inc.COM1,100,000$34.4M5.1%−228,175−17.2%ReducedHistory
INSMINSMED IncCOM PAR $.01475,000$47.8M7.1%+335,000+239.3%AddedHistory
VRNAVerona Pharma plcSPONSORED ADS610,000$57.7M8.5%−5,000−0.8%ReducedHistory

Options (13)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q2 2025
SecurityClassPutsCalls
EXELExelixis, Inc.COM$19.8M$6.61M
AMGNAmgen IncStock–$11.2M
CRSPCRISPR Therapeutics AGNAMEN AKT–$9.73M
CAPRCapricor Therapeutics, Inc.COM NEW$1.74M–
NVAXNovavax IncCOM NEW–$1.57M
QUREuniQure N.V.SHS–$1.39M
OMEROmeros CorpCOM$942.0K–
INMBInmune Bio, Inc.COM$817.7K–
ALTAltimmune, Inc.COM NEW–$774.0K
KPTIKaryopharm Therapeutics Inc.COM NEW–$678.8K
GALTGalectin Therapeutics IncCOM NEW$527.5K–
APGEApogee Therapeutics, Inc.COM$108.6K–
ABUSArbutus Biopharma CorpCOM–$28.7K

Sold out since Q1 2025 (16)

Positions held at the end of Q1 2025 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q1 2025
SecurityClassShares in Q1 2025Value in Q1 2025% of portfolio in Q1 2025History
SPYSPDR S&P 500 ETF TrustETF30,000$16.8M2.6%History
Omeros Corp682143AG7NOTE 5.250% 2/1–$14.3M2.2%–
IMVTImmunovant, Inc.COM430,000$7.35M1.2%History
NBIXNeurocrine Biosciences IncStock50,000$5.53M0.9%History
SLNOSoleno Therapeutics IncCOM50,000$3.57M0.6%History
MAZEMaze Therapeutics, Inc.COM250,000$2.75M0.4%History
KYMRKymera Therapeutics, Inc.COM100,000$2.74M0.4%History
JBIOJade Biosciences, Inc.COM800,000$2.01M0.3%History
MBXMBX Biosciences, Inc.COM175,000$1.29M0.2%History
ETNB89bio, Inc.COM175,000$1.27M0.2%History
MGTXMeiraGTx Holdings plcCOM150,000$1.02M0.2%History
VKTXViking Therapeutics, Inc.COM25,000$603.8K0.1%History
BDTXBlack Diamond Therapeutics, Inc.COM250,000$387.5K0.1%History
CMPXCompass Therapeutics, Inc.COM130,807$248.5K<0.1%History
OMEROmeros CorpCOM9,958$81.9K<0.1%History
ALLKAllakos Inc.COM250,000$56.9K<0.1%History